| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$12,259,884 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$12,259,884 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-12 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
30,206 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-05-12 |
4 |
AS |
$287.33 |
$374,678 |
D/D |
(1,304) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
AS |
$290.32 |
$381,469 |
D/D |
(1,304) |
36,077 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-08-08 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
37,381 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-06 |
4 |
AS |
$300.39 |
$399,022 |
D/D |
(1,304) |
68,645 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-06 |
4 |
OE |
$187.53 |
$244,539 |
D/D |
1,304 |
69,949 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-10-06 |
4 |
OE |
$63.14 |
$88,712 |
D/D |
1,405 |
1,405 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-10-06 |
4 |
AS |
$109.75 |
$154,199 |
D/D |
(1,405) |
0 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-08-31 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
107,807 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2017-08-31 |
4 |
AS |
$160.00 |
$287,360 |
D/D |
(1,796) |
106,011 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-01-22 |
4 |
AS |
$160.00 |
$287,360 |
D/D |
(1,796) |
49,761 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-01-22 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
51,557 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-02-02 |
4 |
AS |
$165.24 |
$298,330 |
D/D |
(1,796) |
49,761 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-02-02 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
51,557 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-02 |
4 |
AS |
$174.59 |
$313,564 |
D/D |
(1,796) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-02 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
40,909 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-02 |
4 |
AS |
$175.36 |
$314,947 |
D/D |
(1,796) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-02 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
40,909 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-10-28 |
4 |
OE |
$63.14 |
$126,280 |
D/D |
2,000 |
2,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-10-28 |
4 |
AS |
$114.75 |
$229,500 |
D/D |
(2,000) |
0 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-09 |
4 |
D |
$422.74 |
$887,331 |
D/D |
(2,099) |
50,733 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-28 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-28 |
4 |
OE |
$131.89 |
$280,266 |
D/D |
2,125 |
41,238 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-07 |
4 |
OE |
$131.89 |
$280,266 |
D/D |
2,125 |
41,238 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-07 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
157 Records found
|
|
Page 2 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
